Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Eugene Przespolewski, PharmD, BCOP, DPLA, shares insights from his presentation at the 2025 OPC meeting in Austin, Texas.

Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.

This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

HER2-low disease demands a different approach from that of HER2-negative disease.

Pharmacists have the potential to help optimize treatment and maximize supportive care management for targeted therapies.

Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.

Extravasation is defined as the inadvertent leakage of a vesicant from the vein into the surrounding tissue.